Q-omics provides the consensus-scored GFM1 profile across patient tissues and cancer cell-line models. GFM1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GFM1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, GFM1 protein abundance shows 21,013 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where GFM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GFM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GFM1 survival associations across molecular data types. GFM1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GFM1 RNA expression–survival associations across cancer types. High GFM1 expression shows unfavorable associations in MESO, PAAD and UCEC, but favorable associations in KIRC, LUSC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GFM1 RNA expression.
This table summarizes GFM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GFM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GFM1 shows lower tumor expression in THCA and KIRC and higher tumor expression in HNSC, STAD, BLCA and LUSC. The HNSC box plot shows higher GFM1 RNA expression in tumor versus normal tissue (log2 FC = +0.805, t-test p < 0.001).
This table shows molecular features associated with GFM1 in patient tissues and cancer cell lines. In patient samples, GFM1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GFM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
